Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SINOPEC CORP
00386
CN Stock MarketDetailed Quotes
Tasly Pharmaceutical Group (600535)
- 14.95
- -0.17-1.12%
Market Closed May 7 15:00 CST
22.33BMarket Cap19.24P/E (TTM)
15.15High14.92Low93.33KlotVolume15.12Open15.12Prev Close139.85MTurnover0.63%Turnover Ratio20.20P/E (Static)1.49BShares17.4852wk High1.75P/B22.33BFloat Cap13.4552wk Low16.63Limit Up1.49BShs Float37.65Historical High13.61Limit Down1.52%Range %-3.46Historical Low0.48Dividend TTM14.98Avg Price49.79KlotAsk3.21%Div Yield TTM100Lot Size41.02KlotBid
Tasly Pharmaceutical Group (600535) Balance Sheet
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Money funds | -73.76%628.35M | -52.04%1.44B | -28.41%2.6B | -37.41%2.79B | -45.08%2.39B | -32.74%2.99B | -15.83%3.64B | 18.86%4.46B | 33.58%4.36B | 42.68%4.45B |
| Transactional financial assets | 242.64%1.83B | 165.68%1.39B | -33.47%886.32M | 7.50%1.44B | 7.35%535.25M | 74.49%524.72M | 2,010.22%1.33B | 336.87%1.34B | -58.23%498.61M | -73.27%300.71M |
| Notes receivable and accounts receivable | 38.85%1.35B | 43.36%1.12B | 13.94%1.19B | 31.25%1.14B | 16.12%970.95M | 13.39%780.14M | 6.22%1.04B | 19.97%868.39M | 9.30%836.13M | -23.23%688M |
| -Accounts receivable | 38.85%1.35B | 43.36%1.12B | 13.94%1.19B | 31.25%1.14B | 16.12%970.95M | 13.39%780.14M | 6.22%1.04B | 19.97%868.39M | 9.30%836.13M | -23.23%688M |
| Other receivables (including interest and dividends) | -31.34%39.71M | 73.30%39.96M | -58.64%35.79M | 13.02%20.18M | 17.45%57.84M | 100.68%23.06M | 271.34%86.55M | -59.77%17.86M | 21.17%49.25M | 27.91%11.49M |
| -Other receivable | ---- | ---- | ---- | 13.02%20.18M | ---- | 100.68%23.06M | ---- | -59.77%17.86M | ---- | 27.91%11.49M |
| Advance payment | 1.95%77.84M | -6.81%57.8M | -21.88%74.43M | -10.38%81.19M | -32.72%76.35M | -5.41%62.03M | -7.85%95.27M | -0.43%90.6M | 13.29%113.48M | -16.02%65.57M |
| Inventories | -10.71%1.44B | -16.64%1.43B | -16.36%1.43B | -14.31%1.56B | -9.91%1.62B | -2.05%1.71B | -1.05%1.71B | 8.14%1.82B | 8.72%1.79B | 14.07%1.75B |
| Receivable financing | -22.90%1.31B | 9.60%1.3B | 33.82%1.55B | -2.69%1.12B | -10.74%1.69B | -17.83%1.19B | -47.87%1.16B | -52.20%1.15B | -28.59%1.9B | -41.15%1.44B |
| Non-current assets due within one year | --1.89B | --1.4B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other current assets | 137.68%54.5M | 80.87%53.7M | 148.89%34.89M | 31.77%25.37M | -3.66%22.93M | 14.84%29.69M | 104.03%14.02M | -18.10%19.25M | -11.47%23.8M | -47.24%25.85M |
| Total current assets | 17.03%8.62B | 12.58%8.23B | -14.02%7.8B | -16.28%8.17B | -23.03%7.37B | -16.28%7.31B | -3.96%9.07B | 8.10%9.76B | -1.29%9.57B | -5.70%8.73B |
| Non Current assets | ||||||||||
| Other non-current financial assets | -41.24%334.23M | -43.04%291.55M | -61.26%186.72M | -53.69%258.7M | -10.57%568.8M | -19.80%511.87M | -34.23%481.96M | -25.14%558.57M | -13.82%636M | 31.56%638.22M |
| Long-term equity investment | -20.91%1.04B | -19.49%1.05B | -6.27%1.28B | -7.17%1.28B | -5.83%1.31B | -7.49%1.31B | -11.10%1.37B | -9.62%1.38B | -9.46%1.39B | 37.95%1.42B |
| Fixed assets | ---- | ---- | ---- | -6.19%3.07B | ---- | -4.62%3.23B | ---- | -4.66%3.27B | ---- | -4.80%3.39B |
| Constru in process | ---- | ---- | ---- | 58.40%312.75M | ---- | 44.12%221.76M | ---- | 7.87%197.44M | ---- | 49.44%153.87M |
| Intangible assets | 35.66%776.98M | 31.49%794.39M | 30.66%779.33M | 2.57%562.15M | 1.92%572.73M | 5.32%604.17M | 1.75%596.48M | -23.37%548.05M | 0.34%561.94M | 24.86%573.64M |
| Development expenditure | -9.55%1.32B | -9.33%1.31B | -16.89%1.28B | -3.33%1.5B | -1.74%1.46B | -0.50%1.45B | 8.73%1.54B | 26.17%1.55B | 26.84%1.49B | 28.81%1.45B |
| Goodwill | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%15.88M | 0.00%15.88M | 0.00%15.88M | 0.00%15.88M |
| Long deferred expense | -3.86%18.95M | 9.56%22.65M | 44.27%22.07M | 10.10%19.09M | -7.07%19.71M | -10.98%20.67M | -12.05%15.3M | -12.11%17.34M | -18.69%21.21M | -19.13%23.22M |
| Deferred tax assets | 16.75%66.65M | 26.11%67.05M | 24.04%49.18M | 22.21%58.01M | 8.50%57.09M | 6.34%53.17M | -25.40%39.65M | -11.30%47.46M | -1.29%52.61M | -43.36%50M |
| Usufruct assets | -9.26%151.83M | -11.93%171.12M | -14.49%164.37M | -16.85%169.98M | -25.35%167.32M | -14.26%194.28M | -4.40%192.22M | 1.52%204.44M | 9.09%224.15M | 2.77%226.6M |
| Other non current assets | -48.10%24.11M | -68.76%22.66M | -13.23%52.18M | -10.25%44.78M | 24.34%46.44M | 68.15%72.54M | 20.28%60.14M | 18.98%49.9M | -62.12%37.35M | -57.74%43.14M |
| Total non current assets | -7.32%7.07B | -7.25%7.11B | -7.80%7.16B | -7.22%7.28B | -3.97%7.63B | -3.96%7.67B | -5.67%7.76B | -3.95%7.85B | -1.55%7.94B | 10.60%7.98B |
| Total assets | 4.65%15.69B | 2.43%15.34B | -11.15%14.96B | -12.25%15.45B | -14.39%15B | -10.40%14.98B | -4.76%16.83B | 2.37%17.6B | -1.41%17.52B | 1.44%16.71B |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Short term loan | 311.15%829.41M | 59.49%1.12B | -53.21%464.76M | -3.52%794.43M | -69.59%201.73M | -3.25%699.54M | -18.25%993.29M | -12.58%823.42M | -29.05%663.37M | 291.95%723.05M |
| Notes payable and accounts payable | -55.78%472.1M | -37.89%376.9M | -69.88%329.26M | -62.91%590.05M | -14.38%1.07B | 5.95%606.81M | 34.98%1.09B | 101.95%1.59B | 47.84%1.25B | -35.49%572.73M |
| -Notes payable | -88.21%78.87M | -75.09%46.85M | -89.86%63.03M | -89.90%110.35M | -5.26%669.16M | 45.87%188.04M | 96.44%621.51M | 392.48%1.09B | 258.18%706.33M | -56.08%128.91M |
| -Accounts payable | -1.32%393.23M | -21.19%330.05M | -43.56%266.23M | -3.67%479.71M | -26.29%398.48M | -5.64%418.77M | -4.41%471.7M | -12.00%497.97M | -16.35%540.57M | -25.31%443.82M |
| Contract liabilities | -33.84%50.02M | -29.78%47.42M | -38.64%52.87M | -33.88%66.5M | -19.13%75.61M | -24.14%67.53M | 9.60%86.17M | 28.90%100.58M | 22.36%93.49M | -3.20%89.02M |
| Advance receipts | -96.16%2.45M | -96.28%2.46M | -3.28%64.16M | -3.88%63.76M | -0.41%63.76M | -0.42%66.08M | 4.04%66.33M | 4.04%66.33M | -11.69%64.02M | 3.46%66.36M |
| Salaries payable | 614.20%239.83M | 159.38%294.67M | 177.97%240.01M | -12.06%56.1M | -9.74%33.58M | -0.61%113.61M | -4.83%86.34M | -17.02%63.79M | -37.77%37.21M | -18.70%114.3M |
| Taxs payable | 96.86%246.81M | 68.82%203.94M | 42.49%138.78M | 42.98%128.02M | 18.00%125.37M | 41.11%120.81M | -2.10%97.39M | -21.89%89.54M | -33.86%106.24M | -55.19%85.61M |
| Other payable (including interest and dividends) | 1,195.62%402.32M | 446.80%209.22M | 862.86%582.2M | -21.42%53.69M | -73.22%31.05M | -79.19%38.26M | -67.07%60.47M | -65.11%68.32M | -26.98%115.97M | 253.16%183.91M |
| -Dividend payable | ---- | ---- | --313.73M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other payable | ---- | ---- | ---- | -21.42%53.69M | ---- | -79.19%38.26M | ---- | -65.11%68.32M | ---- | 253.16%183.91M |
| Non current liabilities due within one year | -90.81%77.99M | -91.39%54.67M | -81.01%166.3M | 42.64%709.07M | 63.47%848.66M | 21.75%634.67M | 96.78%875.71M | 43.22%497.12M | 3.68%519.15M | -1.59%521.28M |
| Other current liabilities | -97.74%179.12K | 27.49%3.04M | -55.47%872.12K | -10.44%3.32M | 23.13%7.93M | -82.09%2.38M | -54.47%1.96M | -9.46%3.71M | 669.81%6.44M | 144.68%13.3M |
| Total current liabilities | -5.47%2.32B | -1.78%2.31B | -39.33%2.04B | -25.39%2.46B | -13.93%2.46B | -0.84%2.35B | 12.39%3.36B | 26.58%3.3B | 1.59%2.85B | 10.35%2.37B |
| Current liabilities | ||||||||||
| Long term loan | 33.32%201.57M | -14.54%216.87M | -26.81%178.84M | -88.72%139.57M | -89.49%151.19M | -82.05%253.76M | -85.75%244.36M | -32.00%1.24B | -23.13%1.44B | 2.75%1.41B |
| Estimate liabilities | ---- | ---- | ---- | ---- | ---- | ---- | --1.42M | ---- | ---- | ---- |
| Deferred tax liabilities | 9,115.50%36.68M | 6,436.39%26.02M | 260.45%398.03K | 260.45%398.03K | -83.12%398.03K | 260.29%398.03K | -99.33%110.43K | -99.38%110.43K | -88.42%2.36M | -99.52%110.48K |
| Long term deferred income | -2.08%188.19M | -1.73%189.95M | 24.98%191.66M | 24.70%193.24M | 20.14%192.19M | 21.54%193.29M | -6.64%153.35M | -6.57%154.96M | -9.49%159.97M | -10.56%159.02M |
| Lease liabilities | -21.78%40.42M | -24.69%51.19M | -17.48%47.13M | -23.07%49.73M | -39.60%51.68M | -16.62%67.97M | -15.15%57.11M | 16.57%64.63M | 21.82%85.56M | 8.26%81.52M |
| Total non current liabilities | 18.05%466.85M | -6.09%484.02M | -8.40%418.03M | -73.73%382.94M | -76.56%395.46M | -68.85%515.41M | -76.76%456.35M | -29.23%1.46B | -21.15%1.69B | 0.15%1.65B |
| Total liabilities | -2.20%2.79B | -2.55%2.79B | -35.63%2.46B | -40.19%2.85B | -37.20%2.85B | -28.80%2.87B | -22.94%3.82B | 1.96%4.76B | -8.24%4.54B | 5.92%4.02B |
| Shareholders equity | ||||||||||
| Paid-in capital | 0.00%1.49B | 0.00%1.49B | 0.00%1.49B | 0.00%1.49B | 0.00%1.49B | -0.38%1.49B | -0.38%1.49B | -0.38%1.49B | -0.38%1.49B | 0.00%1.5B |
| Capital reserve funds | 5.11%482.35M | 5.10%482.39M | -45.38%472.37M | -46.80%459.43M | -46.51%458.9M | -52.10%458.96M | -10.61%864.86M | -18.23%863.56M | -35.50%857.85M | -34.22%958.08M |
| Surplus reserve funds | 0.00%1.74B | 0.00%1.74B | 6.52%1.74B | 6.52%1.74B | 6.52%1.74B | 6.52%1.74B | 7.33%1.64B | 7.33%1.64B | 7.33%1.64B | 7.33%1.64B |
| Retained profit | 10.37%9.02B | 6.04%8.65B | -1.33%8.53B | 2.00%8.63B | -4.85%8.17B | -1.65%8.15B | 2.92%8.64B | 4.84%8.46B | 4.55%8.59B | 5.96%8.29B |
| Less:Treasury stock | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%105.98M |
| Other composite income | -42.26%30.83M | -28.67%37.24M | -3.27%68.04M | -34.04%49.9M | -35.54%53.4M | -40.66%52.22M | -41.38%70.34M | -44.67%75.65M | -14.72%82.84M | -58.41%88M |
| Shareholders equity without minority interests | 7.11%12.77B | 4.21%12.4B | -3.17%12.3B | -1.23%12.38B | -5.83%11.92B | -3.76%11.9B | 2.46%12.71B | 2.86%12.53B | 0.79%12.66B | -0.35%12.37B |
| Minority interests | -39.04%137.77M | -30.97%143.49M | -37.00%195.66M | -28.40%223.33M | -29.15%225.99M | -35.36%207.86M | -2.69%310.55M | -9.28%311.9M | 22.17%318.98M | 21.30%321.59M |
| Total shareholder equity | 6.26%12.91B | 3.60%12.55B | -3.97%12.5B | -1.89%12.6B | -6.41%12.15B | -4.56%12.11B | 2.33%13.02B | 2.53%12.84B | 1.23%12.98B | 0.10%12.69B |
| Total liabilityies and equity | 4.65%15.69B | 2.43%15.34B | -11.15%14.96B | -12.25%15.45B | -14.39%15B | -10.40%14.98B | -4.76%16.83B | 2.37%17.6B | -1.41%17.52B | 1.44%16.71B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
The US-Iran negotiations have entered a critical window period amid external expectations and the strategic interactions of all parties, wit
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm